Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human IL-15-transpresenting WT1-targeting autologous dendritic cell vaccination
2024-515296-35-00Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Dec 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of wilms tumor 1 + interleukin-15 + interleukin-15 receptor alpha mRNA dendritic cell vaccine in pancreatic cancer (PC), esophageal cancer, liver cancer and 1 more, sponsored by Antwerp University Hospital. Primary endpoints: Feasibility of IL-15-transpresenting WT1-targeting DC vaccine and Safety of IL-15-transpresenting WT1-targeting DC vaccination. Started Dec 2023; status: completed.
02
Drugs
wilms tumor 1 + interleukin-15 + interleukin-15 receptor alpha mRNA dendritic cell vaccine
03
Conditions
pancreatic cancer (PC)esophageal cancerliver cancerovarian cancer
Beyond the preview
Go deeper on 2024-515296-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515296-35-00.